Building Bridges is a joint initiative, launched in 2019 by Swiss public authorities, the finance community, the United Nations and other international partners to accelerate the transition to a global economic model aligned with the SDGs.
As part of Building Bridges Week 2021 (29 November – 2 December) in Geneva, please join DNDi for an in-person panel session:
Financing SDG 3 (Health): The Case of Hepatitis C Elimination
Date: Wednesday, 1 December 2021
Time: 16:30-18:00
Venue: Grand Salon, Impact Hub, Geneva
Speakers:
- Genya V. Dana, PhD, Head of Healthcare, World Economic Forum
- Dr Philippa Easterbrook, Senior Scientist, Global Hepatitis Programme, World Health Organization
- Dr Mariam Jashi, EECA Regional Chair, UNITE Global Parliamentarians Network and former President, Leading Group on Innovative Financing for Development
- Dr Toomas Palu, Adviser, Health, Nutrition & Population, World Bank
- Dr Bill Rodriguez, CEO, FIND, the global alliance for diagnostics
Moderator: Greg S Garrett, Director, Business Development & Alliance Management, DNDi
Session overview
The technologies to eliminate many diseases are now available. However, the financing is not. Hepatitis C kills nearly as many as malaria, and yet not one major funder is funding the multi-billion-dollar funding gap. This event will showcase countries that have used innovative finance approaches and South-South collaborations to progress towards hepatitis elimination.
This session will use the case study of hepatitis C and South-South collaboration to showcase how the financing gap for SDG 3 can be filled and directed towards the elimination of diseases. Countries, including Egypt, Malaysia, and Georgia, have shown how innovative financing mechanisms and collaboration between governments, international financing institutions, and private pharmaceutical companies in the Global South can help prevent HCV cases and deaths. This session will look at what has worked and argue for replication of sustainable financing for hepatitis C elimination as well other curable diseases by 2030.
